Cargando…

Interactive Software “Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)” for Cancer Phase I Clinical Trials

Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS) is a novel Phase I design that integrates the novel toxicity scoring system originally proposed by Chen et al. [1] and the original Isotonic Design proposed by Leung et al. [2]. ID-NETS has substantially improved the accuracy of ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhengjia, Wang, Zhibo, Wang, Haibin, Owonikoko, Taofeek K, Kowalski, Jeanne, Khuri, Fadlo R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Open 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680993/
https://www.ncbi.nlm.nih.gov/pubmed/23847695
http://dx.doi.org/10.2174/1874431101307010008
_version_ 1782273191251542016
author Chen, Zhengjia
Wang, Zhibo
Wang, Haibin
Owonikoko, Taofeek K
Kowalski, Jeanne
Khuri, Fadlo R
author_facet Chen, Zhengjia
Wang, Zhibo
Wang, Haibin
Owonikoko, Taofeek K
Kowalski, Jeanne
Khuri, Fadlo R
author_sort Chen, Zhengjia
collection PubMed
description Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS) is a novel Phase I design that integrates the novel toxicity scoring system originally proposed by Chen et al. [1] and the original Isotonic Design proposed by Leung et al. [2]. ID-NETS has substantially improved the accuracy of maximum tolerated dose (MTD) estimation and trial efficiency in the Phase I clinical trial setting by fully utilizing all toxicities experienced by each patient and treating toxicity response as a quasi-continuous variable instead of a binary indicator of dose limiting toxicity (DLT). To facilitate the incorporation of the ID-NETS method into the design and conduct of Phase I clinical trials, we have designed and developed a user-friendly software, ID-NETS(©TM), which has two functions: 1) Calculating the recommended dose for the subsequent patient cohort using available completed data; and 2) Performing simulations to obtain the operating characteristics of a trial designed with ID-NETS. Currently, ID-NETS(©TM)v1.0 is available for free download at http://winshipbbisr.emory.edu/IDNETS.html.
format Online
Article
Text
id pubmed-3680993
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Bentham Open
record_format MEDLINE/PubMed
spelling pubmed-36809932013-07-11 Interactive Software “Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)” for Cancer Phase I Clinical Trials Chen, Zhengjia Wang, Zhibo Wang, Haibin Owonikoko, Taofeek K Kowalski, Jeanne Khuri, Fadlo R Open Med Inform J Article Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS) is a novel Phase I design that integrates the novel toxicity scoring system originally proposed by Chen et al. [1] and the original Isotonic Design proposed by Leung et al. [2]. ID-NETS has substantially improved the accuracy of maximum tolerated dose (MTD) estimation and trial efficiency in the Phase I clinical trial setting by fully utilizing all toxicities experienced by each patient and treating toxicity response as a quasi-continuous variable instead of a binary indicator of dose limiting toxicity (DLT). To facilitate the incorporation of the ID-NETS method into the design and conduct of Phase I clinical trials, we have designed and developed a user-friendly software, ID-NETS(©TM), which has two functions: 1) Calculating the recommended dose for the subsequent patient cohort using available completed data; and 2) Performing simulations to obtain the operating characteristics of a trial designed with ID-NETS. Currently, ID-NETS(©TM)v1.0 is available for free download at http://winshipbbisr.emory.edu/IDNETS.html. Bentham Open 2013-04-05 /pmc/articles/PMC3680993/ /pubmed/23847695 http://dx.doi.org/10.2174/1874431101307010008 Text en © Chen et al.; Licensee Bentham Open. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Chen, Zhengjia
Wang, Zhibo
Wang, Haibin
Owonikoko, Taofeek K
Kowalski, Jeanne
Khuri, Fadlo R
Interactive Software “Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)” for Cancer Phase I Clinical Trials
title Interactive Software “Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)” for Cancer Phase I Clinical Trials
title_full Interactive Software “Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)” for Cancer Phase I Clinical Trials
title_fullStr Interactive Software “Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)” for Cancer Phase I Clinical Trials
title_full_unstemmed Interactive Software “Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)” for Cancer Phase I Clinical Trials
title_short Interactive Software “Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)” for Cancer Phase I Clinical Trials
title_sort interactive software “isotonic design using normalized equivalent toxicity score (id-nets©tm)” for cancer phase i clinical trials
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680993/
https://www.ncbi.nlm.nih.gov/pubmed/23847695
http://dx.doi.org/10.2174/1874431101307010008
work_keys_str_mv AT chenzhengjia interactivesoftwareisotonicdesignusingnormalizedequivalenttoxicityscoreidnetstmforcancerphaseiclinicaltrials
AT wangzhibo interactivesoftwareisotonicdesignusingnormalizedequivalenttoxicityscoreidnetstmforcancerphaseiclinicaltrials
AT wanghaibin interactivesoftwareisotonicdesignusingnormalizedequivalenttoxicityscoreidnetstmforcancerphaseiclinicaltrials
AT owonikokotaofeekk interactivesoftwareisotonicdesignusingnormalizedequivalenttoxicityscoreidnetstmforcancerphaseiclinicaltrials
AT kowalskijeanne interactivesoftwareisotonicdesignusingnormalizedequivalenttoxicityscoreidnetstmforcancerphaseiclinicaltrials
AT khurifadlor interactivesoftwareisotonicdesignusingnormalizedequivalenttoxicityscoreidnetstmforcancerphaseiclinicaltrials